CIMAvax-EGF + KRAS G12C Inhibitor for Non-Small Cell Lung Cancer

This trial explores a combination of a vaccine called CIMAvax-EGF and a KRAS G12C inhibitor (either sotorasib or adagrasib) to treat advanced non-small cell lung cancer. The researchers aim to determine if this combination can help the immune system fight cancer by blocking signals that promote cancer cell growth. Individuals with non-small cell lung cancer featuring a specific mutation called KRAS G12C, especially those experiencing disease progression, might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering a chance to potentially benefit from an innovative therapy.

The trial does not specify if you need to stop taking your current medications. However, you cannot have received anticancer chemotherapy within 4 weeks before starting the study drug, and certain conditions apply if you are on corticosteroids or have had recent surgery.

Research has shown that CIMAvax-EGF is generally safe for patients, having been tested in over 5,000 people with non-small cell lung cancer (NSCLC). The most common side effects are mild, including reactions at the injection site, fever, and chills, and are usually easy to manage.

Studies indicate that adagrasib is well tolerated in patients with a specific type of NSCLC called KRAS G12C mutation. While most side effects are mild, some patients needed to adjust their dose due to these effects. Recent research has not identified any new safety concerns.

Sotorasib is considered safe and has received FDA approval for treating advanced NSCLC with KRAS G12C mutations. Studies have shown it has a manageable safety profile, with no new safety issues reported. Common side effects include liver-related problems, which are generally controllable.

Researchers are excited about the combination treatment of CIMAvax-EGF with KRAS G12C inhibitors like adagrasib or sotorasib for non-small cell lung cancer because it targets a specific mutation that many standard therapies do not directly address. CIMAvax-EGF is an active immunotherapy that stimulates the body's immune response against cancer cells by targeting the epidermal growth factor (EGF). Meanwhile, KRAS G12C inhibitors specifically target a genetic mutation in cancer cells that is notoriously difficult to treat. This dual approach not only aims to enhance the immune system's response but also directly inhibits a key driver of tumor growth, offering a potentially more effective treatment strategy compared to conventional chemotherapies or radiation.

Research has shown that CIMAvax-EGF can aid individuals with advanced non-small cell lung cancer (NSCLC) by enhancing the immune system's ability to combat cancer cells. Studies found that patients using CIMAvax-EGF had a 3-year survival rate of up to 29%, and it is considered safe. In this trial, participants will receive CIMAvax-EGF combined with a KRAS G12C inhibitor.

Adagrasib, one of the KRAS G12C inhibitors studied in this trial, has shown promise in treating this lung cancer. It increased the time patients lived without cancer progression from 3.8 months to 5.5 months.